Stay updated on Anti-PD-1+Radiation in Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Anti-PD-1+Radiation in Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Anti-PD-1+Radiation in Metastatic Breast Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe site revision label in the footer changed from v3.8.0 to v3.8.1, with no apparent change to the study record.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe record now presents details for a completed Phase Ib/II study of nivolumab with radiation therapy for HER2-negative metastatic breast cancer, including participant criteria, study design, and publication information.SummaryDifference38%

- Check22 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0 while the study record continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedA sitewide notice announces NIH website transition updates and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check36 days agoChange DetectedThe footer’s site revision label advances from v3.7.1 to v3.7.2. The page still displays a 403 Forbidden error instead of the study record.SummaryDifference0.2%

- Check43 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

Stay in the know with updates to Anti-PD-1+Radiation in Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anti-PD-1+Radiation in Metastatic Breast Cancer Clinical Trial page.